This was further supported by a 2012 study by Morganti et al. (2012), where AAV9 delivery of soluble FKN was neuroprotective in the MPTP model of PD, treatment with AAV overexpressing FKN resulting in reduced neurotoxic effects. Here, CX3CL1 is linked to Parkinson disease.